Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (762)	3/26/2007 7:06:29 PM
From: keokalani'nui	Respond to of 824

Plus, I don't do post-commercialization well. Not that I ever really see it where I invest.

To: IRWIN JAMES FRANKEL who wrote (762)	3/26/2007 9:29:19 PM
From: Robohogs	Read Replies (1) \| Respond to of 824

True. But assume you do not object to this profiteer eating the copay, at least in the sense that it reduces the price of Soliris for some. :-) It does defeat the purpose of having a copay - a sham, futile. How does this work in practice - it negates the whole co-pay and could encourage drug company to set price at many times what it should since it more than makes up the co-pay in extra insurance proceeds. Deductibles and co-pays are there for a reason. Jon